OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Zamarin Discusses Ongoing Work With Immunotherapy in Ovarian Cancer

May 15th 2019

Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses ongoing work with immunotherapy in patients with advanced ovarian cancer.

Dr. Mizrahi on the Importance of Early Genomic Testing in CRC

May 15th 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of early genomic testing in patients with colorectal cancer.

Dr. McGregor on Data Evaluating the Link Between Cardiac Complications and ADT in Prostate Cancer

May 15th 2019

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the data behind the potential link between cardiac complications and androgen deprivation therapy (ADT) in prostate cancer.

Dr. Chhabra on Impactful Advances in Relapsed/Refractory Multiple Myeloma

May 15th 2019

Saurabh Chhabra, MD, MS, assistant professor at the Medical College of Wisconsin, discusses the most impactful advances made in relapsed/refractory multiple myeloma.

Dr. Mason on Progress Made in Resectable Stage III Lung Cancer

May 15th 2019

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Health, chief of lung transplantation, head of the Department of Thoracic Surgery, Baylor University Medical Center, discusses the progress that has been made in resectable stage III lung cancer.

Dr. Davids Discusses Ongoing Research With Ibrutinib Plus Venetoclax in CLL

May 15th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses ongoing research with ibrutinib plus venetoclax in chronic lymphocytic leukemia.

Dr. Galal on CAR T-Cell Therapy in Relapsed/Refractory Lymphomas

May 15th 2019

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the use of CAR T-cell therapy in patients with relapsed/refractory lymphomas.

Dr. Goy on the Significance of Becoming an NCI-Designated Cancer Center

May 15th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the significance of becoming a National Cancer Institute-designated cancer center.

Dr. Kelly on the Outlook of ALK-Positive NSCLC

May 14th 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the 10 Baylor Scott & White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the outlook of patients with ALK-positive non–small cell lung cancer (NSCLC).

Dr. Quinn on the Biology of RCC

May 14th 2019

David I. Quinn, MD, MBBS, PhD, FRACP, FACP, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Department of Medicine, Keck School of Medicine, discusses the biology of renal cell carcinoma (RCC).

Dr. Kim Discusses Minimally Invasive Surgery and Laparotomic Surgery in Cervical Cancer

May 14th 2019

Se Ik Kim, MD, research fellow, Department of Obstetrics and Gynecology, Seoul National University Hospital, discusses the use of minimally invasive surgery and laparotomic surgery in patients with cervical cancer.

Dr. Lekakis on Managing the Toxicity of CAR T-Cell Therapy

May 13th 2019

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses managing the toxicity of CAR T-cell therapy.

Dr. Kopetz on the Significance of Tumor Sidedness in CRC

May 13th 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the significance of tumor sidedness in colorectal cancer.

Dr. Papadimitrakopoulou on the Utility of Liquid Biopsies in NSCLC

May 11th 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, discusses the utility of liquid biopsies in non–small cell lung cancer (NSCLC).

Dr. Pecora on JTCC Joining Georgetown Lombardi Cancer Consortium

May 11th 2019

Andrew L. Pecora, MD, FACP, CPE, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses John Theurer Cancer Center (JTCC) joining Georgetown Lombardi Cancer Consortium.

Dr. Weiner on the Criteria Required to Become an NCI-Designated Cancer Center

May 10th 2019

Louis M. Weiner, MD, director of the Georgetown Lombardi Comprehensive Cancer Center, discusses the criteria required to become an NCI-designated cancer center.

Dr. McGregor on Frontline Regimens in Advanced RCC

May 10th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses frontline treatment regimens in advanced renal cell carcinoma (RCC).

Importance of Quality of Life Endpoints in Clinical Trials

May 10th 2019

Massimo Di Maio, PhD, medical oncologist, Mauriziano Hospital, professor of medical oncology, University of Turin, discusses the importance of quality of life (QoL) endpoints in clinical trials.

Dr. Choudhury on Immunotherapy in Metastatic CRPC

May 10th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses data with immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Schlumbrecht on Investigational Treatment Strategies in Uterine Leiomyosarcoma

May 9th 2019

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational treatment strategies in uterine leiomyosarcoma.